JP2004530699A5 - - Google Patents

Download PDF

Info

Publication number
JP2004530699A5
JP2004530699A5 JP2002591027A JP2002591027A JP2004530699A5 JP 2004530699 A5 JP2004530699 A5 JP 2004530699A5 JP 2002591027 A JP2002591027 A JP 2002591027A JP 2002591027 A JP2002591027 A JP 2002591027A JP 2004530699 A5 JP2004530699 A5 JP 2004530699A5
Authority
JP
Japan
Prior art keywords
alkyl
group
pharmaceutical composition
groups
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2002591027A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004530699A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2002/015775 external-priority patent/WO2002094311A1/en
Publication of JP2004530699A publication Critical patent/JP2004530699A/ja
Publication of JP2004530699A5 publication Critical patent/JP2004530699A5/ja
Pending legal-status Critical Current

Links

JP2002591027A 2001-05-21 2002-05-17 ドライアイ障害を処置するためのプロテオソームインヒビターの使用 Pending JP2004530699A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29272201P 2001-05-21 2001-05-21
PCT/US2002/015775 WO2002094311A1 (en) 2001-05-21 2002-05-17 Use of proteasome inhibitors to treat dry eye disorders

Publications (2)

Publication Number Publication Date
JP2004530699A JP2004530699A (ja) 2004-10-07
JP2004530699A5 true JP2004530699A5 (enExample) 2005-12-22

Family

ID=23125916

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002591027A Pending JP2004530699A (ja) 2001-05-21 2002-05-17 ドライアイ障害を処置するためのプロテオソームインヒビターの使用

Country Status (17)

Country Link
US (1) US6740674B2 (enExample)
EP (1) EP1392355B1 (enExample)
JP (1) JP2004530699A (enExample)
CN (1) CN1509183A (enExample)
AT (1) ATE353667T1 (enExample)
AU (1) AU2002308760B2 (enExample)
BR (1) BR0209883A (enExample)
CA (1) CA2447909C (enExample)
CY (1) CY1107531T1 (enExample)
DE (1) DE60218153T2 (enExample)
DK (1) DK1392355T3 (enExample)
ES (1) ES2278049T3 (enExample)
MX (1) MXPA03010634A (enExample)
PL (1) PL367287A1 (enExample)
PT (1) PT1392355E (enExample)
WO (1) WO2002094311A1 (enExample)
ZA (1) ZA200308768B (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005099687A2 (en) * 2004-04-09 2005-10-27 President And Fellows Of Harvard College Analogs of salinosporamide a
US20060167106A1 (en) * 2004-11-19 2006-07-27 Mei Zhang Compounds acting at the centrosome
US7465720B2 (en) 2005-09-12 2008-12-16 President And Fellows Of Harvard College Proteasome inhibiting β-lactam compounds
EP2623113B1 (en) 2005-11-09 2017-05-31 Onyx Therapeutics, Inc. Compound for enzyme inhibition
NZ597545A (en) 2006-06-19 2013-07-26 Proteolix Inc Peptide epoxyketones for proteasome inhibition
CA2701778C (en) 2007-10-04 2018-09-11 Onyx Therapeutics, Inc. Crystalline peptide epoxy ketone protease inhibitors and the synthesis of amino acid keto-epoxides
JP5675629B2 (ja) 2008-10-21 2015-02-25 オニキス セラピューティクス, インク.Onyx Therapeutics, Inc. ペプチドエポキシケトンを用いた併用療法
AR075899A1 (es) 2009-03-20 2011-05-04 Onyx Therapeutics Inc Tripeptidos epoxicetonas cristalinos inhibidores de proteasa
WO2011060179A1 (en) 2009-11-13 2011-05-19 Onyx Therapeutics, Inc Use of peptide epoxyketones for metastasis suppression
AU2011223795B2 (en) 2010-03-01 2015-11-05 Onyx Therapeutics, Inc. Compounds for immunoproteasome inhibition
CA2795559A1 (en) 2010-04-07 2011-11-03 Onyx Therapeutics, Inc. Crystalline peptide epoxyketone immunoproteasome inhibitor
US9126997B1 (en) 2010-09-07 2015-09-08 Northwestern University Synergistic effect of glucocorticoid receptor agonists in combination with proteosome inhibitors for treating leukemia and myeloma
WO2014011695A2 (en) 2012-07-09 2014-01-16 Onyx Therapeutics, Inc. Prodrugs of peptide epoxy ketone protease inhibitors
CN103893742B (zh) * 2014-03-03 2016-01-20 中山大学中山眼科中心 含卵黄膜外层蛋白1在制备治疗干眼药物中的应用
CN107151255A (zh) * 2016-03-06 2017-09-12 复旦大学 硼酸类化合物及其制备方法和用途

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3991759A (en) 1975-10-28 1976-11-16 Alza Corporation Method and therapeutic system for treating aqueous deficient dry eye
US4131651A (en) 1977-10-25 1978-12-26 Barnes-Hind Pharmaceuticals, Inc. Treatment of dry eye
US4409205A (en) 1979-03-05 1983-10-11 Cooper Laboratories, Inc. Ophthalmic solution
US4370325A (en) 1979-03-30 1983-01-25 Dermik Laboratories Pharmaceutical compositions and method of treatment
US4744980A (en) 1986-04-28 1988-05-17 Holly Frank J Ophthalmic solution for treatment of dry eye syndrome
US4883658A (en) 1986-04-28 1989-11-28 Holly Frank J Ophthalmic solution for treatment of dry-eye syndrome
US4804539A (en) 1986-07-28 1989-02-14 Liposome Technology, Inc. Ophthalmic liposomes
US4818537A (en) 1986-10-21 1989-04-04 Liposome Technology, Inc. Liposome composition for treating dry eye
US4966773A (en) 1986-11-25 1990-10-30 Alcon Laboratories, Inc. Topical ophthalmic compositions containing microfine retinoid particles
US5278151A (en) 1987-04-02 1994-01-11 Ocular Research Of Boston, Inc. Dry eye treatment solution
US4914088A (en) 1987-04-02 1990-04-03 Thomas Glonek Dry eye treatment solution and method
US5075104A (en) 1989-03-31 1991-12-24 Alcon Laboratories, Inc. Ophthalmic carboxy vinyl polymer gel for dry eye syndrome
US5174988A (en) 1989-07-27 1992-12-29 Scientific Development & Research, Inc. Phospholipid delivery system
US5583150A (en) 1989-08-18 1996-12-10 Alcon Laboratories, Inc. 5-methyl-isoxazole-4-carboxylic acid anilides and 2-hydroxyethylidene-cyano acetic anilides for the treatment of ocular diseases
US5041434A (en) 1991-08-17 1991-08-20 Virginia Lubkin Drugs for topical application of sex steroids in the treatment of dry eye syndrome, and methods of preparation and application
ATE132366T1 (de) 1990-05-29 1996-01-15 Boston Ocular Res Zusammensetzung zur behandlung von dry eye erkrankungen
ZA912797B (en) 1990-05-29 1992-12-30 Boston Ocular Res Dry eye treatment process and solution
DK0495421T3 (da) 1991-01-15 1996-12-09 Alcon Lab Inc Anvendelse af carragenaner i topiske ophthalmiske sammensætninger
ZA927277B (en) 1991-10-02 1993-05-19 Boston Ocular Res Dry eye treatment process and solution.
US5958912A (en) 1992-04-21 1999-09-28 The Schepens Eye Research Institute, Inc. Ocular therapy in keratoconjunctivitis sicca using topically applied androgens of TGF-β
JPH07508716A (ja) 1992-04-21 1995-09-28 ザ スキーペンズ アイ リサーチ インスティテュート,インコーポレイテッド シェーグレン症候群における眼のアンドロゲン療法
US6107289A (en) 1992-04-21 2000-08-22 The Schepens Eye Research Institute, Inc. Ocular therapy in keratoconjunctivitis sicca using topically applied androgens or TGF-β
US5290572A (en) 1992-08-06 1994-03-01 Deo Corporation Opthalmic composition for treating dry eye
US5474979A (en) 1994-05-17 1995-12-12 Allergan, Inc. Nonirritating emulsions for sensitive tissue
US6083903A (en) 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
US6335358B1 (en) 1995-04-12 2002-01-01 President And Fellows Of Harvard College Lactacystin analogs
US5696166A (en) 1995-10-31 1997-12-09 Yanni; John M. Compositions containing hydroxyeicosatetraenoic acid derivatives and methods of use in treating dry eye disorders
WO1997020578A1 (en) 1995-12-04 1997-06-12 University Of Miami Non-preserved topical corticosteroid for treatment of dry eye, filamentary keratitis, and delayed tear clearance
JPH1036289A (ja) 1996-07-24 1998-02-10 Sumitomo Pharmaceut Co Ltd 神経細胞の変性または死滅抑制剤
US6071904A (en) 1996-12-11 2000-06-06 Alcon Laboratories, Inc. Process for manufacturing ophthalmic suspensions
US5800807A (en) 1997-01-29 1998-09-01 Bausch & Lomb Incorporated Ophthalmic compositions including glycerin and propylene glycol
US6271199B2 (en) 1997-02-15 2001-08-07 Millennium Pharmaceuticals, Inc. Treatment of infarcts
AU9580098A (en) 1997-09-25 1999-04-12 Millennium Pharmaceuticals, Inc. Proteasome inhibitors, ubiquitin pathway inhibitors or agents that interfere with the activation of nf-(k)b via the ubiquitin proteasome pathway to treat inflammatory and autoimmune diseases
CA2219867A1 (en) 1997-10-31 1999-04-30 Jiangping Wu The use of proteasome inhibitors for treating cancer, inflammation, autoimmune disease, graft rejection and septic shock
PT1037627E (pt) 1998-07-14 2001-11-30 Alcon Lab Inc Utilizacao do acido 11-(3-dimetilaminopropilideno)-6,11-dihidrodibenz¬b,e|oxepin-2-acetico e seus sais derivados farmaceuticamente aceitaveis para a producao de um medicamento para o tratamento de doencas inflamatorias oftalmicas nao-alergicas e para a prebencao da neovascularizacao ocular
US6096733A (en) 1998-12-10 2000-08-01 Virginia Lubkin Drugs for topical application of sex steroids in the treatment of dry eye syndrome, and methods of preparation and application
WO2000043000A1 (en) 1999-01-20 2000-07-27 Kyowa Hakko Kogyo Co., Ltd. Proteasome inhibitors
US6254860B1 (en) 1999-04-13 2001-07-03 Allergan Sales, Inc. Ocular treatment using cyclosporin-A derivatives
ATE270268T1 (de) 1999-04-27 2004-07-15 Novartis Pharma Gmbh 2,4-diamino-3-hydroxycarboxylsäurederivate als proteasome inhibitoren

Similar Documents

Publication Publication Date Title
RU2395500C2 (ru) 2,4-пиримидиндиамины, применяемые в лечении неопластических болезней, воспалительных и иммунных расстройств
MY136034A (en) New medicaments for the treatment of chronic obstructive pulmonary disease
CY1107850T1 (el) Παραγωγα θειαδιαζολυλοπιπεραζiνης mε χρησιμοτητα στην αποτροπη ή στην αγωγη εναντι tου αλγους
EA201000643A1 (ru) Замещенное производное этилендиамина для лечения микобактериальных заболеваний и фармацевтическая композиция на его основе
TNSN04246A1 (fr) Derives d'heteroarylamides benzocondenses de thienopyridines utiles comme agents therapeutiques, compositions pharmaceutiques les contenant et methodes pour leur utilisation
JP2002501049A5 (enExample)
SE0302760D0 (sv) New compounds
TNSN04165A1 (en) Substituted hydroxyethylamines
JP2001526218A5 (enExample)
SE0301886D0 (sv) New use V
WO2004026863A8 (en) Novel oxazole and thiazole compounds as transforming growth factor (tgf) inhibitors
UA85708C2 (ru) Лекарственные комбинации, содержащие бензоксазины, для лечения заболеваний дыхательных путей
YU24503A (sh) Novi tiadiazoli i oksadiazoli i njihova upotreba kao inhibitora fosfodiesteraze-7
PT1251846E (pt) Taxanos com carbonato c-4
JP2003522198A5 (enExample)
RU2007119390A (ru) Соединения 4-метоксиметил-пирролидин-2-карбоновой кислоты и их производные - ингибиторы вируса гепатита с
SG162614A1 (en) Bicyclic 6-alkylidene-penems as beta-lactamases inhibitors
RU2007131435A (ru) Противоопухолевое средство
PT871626E (pt) Triazolonas utilizadas como inibidores de sintese da apoliproteina b
JP2003509494A5 (enExample)
TW200640465A (en) New pharmaceutically active compounds for the treatment of respiratory diseases
RU2003104017A (ru) Ингибиторы тромбина, содержащие аминоизохинолиновую группу
SE0102641D0 (sv) Novel compounds
RU2007121705A (ru) Антиинфекционные липопептиды
JP2008519848A5 (enExample)